In agreement with a crucial role of EZH2 in PCa NED, EZH2 inhibitors are potential agents for NEPC treatment and have been shown to re-sensitize tumors to AR-signaling inhibitors in CRPC (Clermont et al., 2015; Beltran et al., 2016). This evidence concerns the gene EZH2 and posterior cortical atrophy.